Converge Bio
PrivateLast Round
Grant
Jun 2, 2026
Est. Valuation
$90M
Total Funding Raised
$33M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Converge Bio is a biotechnology company that provides a generative AI platform using large language models trained on biological and chemical data to accelerate drug discovery and development for pharmaceutical companies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, NLP & Conversational AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Converge Bio Comparables
Compare Converge Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ainnocence | 82% | |
| Chai Discovery | 82% | |
| EvolutionaryScale | 81% |
Converge Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 2, 2026 | ||||
| Early Stage VC | Apr 28, 2026 | ||||
| Series A | Jan 13, 2026 | ||||
| Seed | Nov 20, 2024 |
Key People
Founding team and executive leadership
Converge Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saras Capital | Series A |
| Vintage Investment Partners | Series A |
| TLV Partners | Series A, Seed |
| Bill & Melinda Gates Foundation | Grant |
| Bessemer Venture Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
$3M grant received from Bill & Melinda Gates Foundation.
- Apr 28, 2026
$25M raised in early stage VC round.
Converge Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Converge Bio's valuation, stock price, and market status.
Is Converge Bio a public or private company?
Converge Bio is a private company.
What is the current stock price of Converge Bio?
Converge Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Converge Bio worth (valuation)?
Converge Bio's valuation is estimated at $90.0M based on funding round data.
Can I buy Converge Bio stock?
Converge Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Converge Bio's last funding round?
Converge Bio's most recent funding round was Early Stage VC on January 13, 2026.
Who are the main investors in Converge Bio?
Key investors in Converge Bio include TLV Partners, Bessemer Venture Partners.
Will Converge Bio IPO soon?
No public IPO plans have been announced for Converge Bio.
How can I track Converge Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Converge Bio's secondary market activity and sign up for updates.